Enzyvant Revenue and Competitors
Estimated Revenue & Valuation
- Enzyvant's estimated annual revenue is currently $5.1M per year.
- Enzyvant's estimated revenue per employee is $155,000
Employee Data
- Enzyvant has 33 Employees.
- Enzyvant grew their employee count by -53% last year.
Enzyvant's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Global Business Excellence & PMO | Reveal Email/Phone |
2 | SVP, CMC | Reveal Email/Phone |
3 | SVP, Platform Head for T-Cell Generation | Reveal Email/Phone |
4 | SVP, Regulatory Affairs, Pharmacovigilance, and Quality | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Senior Director- Nonclinical Development and Translational Sciences | Reveal Email/Phone |
7 | Associate Director CMC Regulatory Affairs | Reveal Email/Phone |
8 | Associate Director, Quality Control | Reveal Email/Phone |
9 | Associate Director, CMC | Reveal Email/Phone |
10 | Associate Director, CMC Manufacturing Science and Technology | Reveal Email/Phone |
Enzyvant Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Enzyvant?
About Enzyvant Enzyvant is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant's lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the US Food and Drug Administration expedited designation as a Regenerative Medicine Advanced Therapy (RMAT). Enzyvant is part of Sumitovant Biopharma (wholly owned by Sumitomo Dainippon Pharma), a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the US, China and the EU as well as talent, knowledge and resources across a wide spectrum of technologies and therapeutic areas.
keywords:N/A
N/A
Total Funding
33
Number of Employees
$5.1M
Revenue (est)
-53%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Enzyvant News
Enzyvant, which focuses on developing regenerative medicines for rare diseases, has laid out plans to build a.
Sumitomo will codevelop the site with Enzyvant. BioCentriq acquired by South Korean company. GC has signed a deal to acquire New Jersey-based...
CAMBRIDGE, Mass. and BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.5M | 33 | -65% | $151.3M |
#2 | $3.8M | 33 | N/A | N/A |
#3 | $4M | 33 | -15% | N/A |
#4 | $5.1M | 33 | -3% | N/A |
#5 | $4M | 33 | 14% | N/A |